<SEC-DOCUMENT>0001564590-21-045220.txt : 20210820
<SEC-HEADER>0001564590-21-045220.hdr.sgml : 20210820
<ACCEPTANCE-DATETIME>20210819194542
ACCESSION NUMBER:		0001564590-21-045220
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210819
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210820
DATE AS OF CHANGE:		20210819

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		211191418

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-8k_20210819.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-19T17:58:29.0271670+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 0f7a9da9dd1942fe9de0abfc928a7dba -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20210819" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-8k_20210819.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20210819_20210819">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20210819_20210819">0000921299</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20210819.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20210819_20210819">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-08-19</xbrli:startDate>
					<xbrli:endDate>2021-08-19</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20210819_20210819">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20210819_20210819" format="ixt:datemonthdayyearen">August 19, 2021</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000921299_20210819_20210819">FibroGen, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:31.67%;"></td>
<td style="width:0.83%;"></td>
<td style="width:34.51%;"></td>
<td style="width:0.99%;"></td>
<td style="width:32%;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000921299_20210819_20210819">001-36740</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20210819_20210819">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20210819_20210819">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20210819_20210819">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20210819_20210819">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20210819_20210819">94158</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000921299_20210819_20210819">415</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20210819_20210819">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="bottom" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000921299_20210819_20210819">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style="width:30%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000921299_20210819_20210819">FGEN</ix:nonNumeric></p></td>
<td valign="top" style="width:35%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.33%;text-indent:-23.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20210819_20210819" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:2pt;border-bottom:Double 2.25pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_1">Item 8.01</p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Events.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 19, 2021, FibroGen, Inc. and its collaboration partner, Astellas Pharma Inc., issued a press release in which they announced that the European Commission has approved EVRENZO<span style="Background-color:#FFFFFF;font-size:10.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></span> (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of such press release is filed as Exhibit&#160;99.1 to this report and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;" id="part_1_2_2">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01</p></td>
<td valign="bottom" style="width:91%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:101.11%;">
<tr>
<td style="width:2.18%;"></td>
<td style="width:6.16%;"></td>
<td style="width:1.67%;"></td>
<td style="width:50.46%;"></td>
<td style="width:40.65%;"></td>
</tr>
<tr style="height:7.8pt;">
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td colspan="3" valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:10.8pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6pt;;text-indent:-6pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td colspan="2" valign="middle" style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex991_35.htm"><span style="text-decoration:underline;">Press Release titled &#8220;Astellas Receives European Commission Approval for First-in-Class EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease&#8221; dated August 19, 2021</span></a></p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_3">SIGNATURES</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIBROGEN, INC.</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: August 19, 2021</p></td>
<td colspan="3" valign="bottom" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:0.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:47.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Lowenstein</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:47.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Lowenstein</p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:47.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex991_35.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex991_35.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;color:#444142;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0r02nlhhqpu000001.jpg" title="" alt="" style="width:273px;height:67px;"></p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0r02nlhhqpu000002.jpg" title="" alt="" style="width:228px;height:62px;"></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0r02nlhhqpu000003.jpg" title="" alt="" style="width:617px;height:107px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;"><a name="_Hlk75514456"></a>&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:18pt;font-family:Times New Roman;letter-spacing:-0.4pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk519256947"></a>Astellas Receives European Commission Approval for First-in-Class EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOKYO, August 19, 2021<font style="font-weight:normal;"> &#8211; </font><font style="Background-color:#FFFFFF;font-weight:normal;">Astellas Pharma Inc. (TSE: 4503, President and CEO:&#160;Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO:&#160;Enrique Conterno, "FibroGen") </font><font style="font-weight:normal;">today announced that the European Commission (EC) has approved </font><font style="Background-color:#FFFFFF;font-weight:normal;">EVRENZO<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are very pleased EVRENZO has been approved as the first oral HIF-PH inhibitor to treat adult patients with symptomatic anemia associated with CKD in the European Union,&#8221; said&#160;Steven Benner, M.D., M.H.S., President of Development, Astellas. &#8220;Today&#8217;s approval provides patients, regardless of dialysis status, with a first-in-class treatment option to address the multifaceted nature of this condition. We look forward to making roxadustat available to adult patients with anemia of CKD in countries across the European Union.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CKD impacts one in 10 people globally, of whom one in five are affected by anemia.<sup style="font-size:85%;line-height:120%;vertical-align:top">1, 2</sup> Anemia of CKD is often untreated or not treated to target, and is associated with reduced quality of life and progression to adverse cardiovascular (CV) and renal outcomes.<sup style="font-size:85%;line-height:120%;vertical-align:top">3-5</sup> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk77155114"></a>&#8220;Anemia is a significant and early complication of CKD that occurs with greater frequency and impact as CKD worsens, affecting patients&#8217; day-to-day living, self-care and mobility,&#8221; said Jonathan Barratt, Ph.D., FRCP, Consultant Nephrologist and the Mayer Professor of Renal Medicine at the University of Leicester, United Kingdom. &#8220;This approval represents a step forward in providing patients with an efficient and simple option to manage anemia symptoms and maintain target hemoglobin levels to minimize the impact on their quality of life.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is the first orally administered HIF-PH inhibitor available in the European Union. Roxadustat increases hemoglobin (Hb) levels through a different mechanism of action compared to injectable erythropoiesis-stimulating agents (ESAs) which are typically co-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administered with intravenous iron</font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As a HIF-PH inhibitor, </font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">roxadustat</font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> activates the body&#8217;s natural response to reduced oxygen levels in the blood. This response involves the regulation of multiple, coordinated processes that </font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allow management</font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of anemia with a reduced </font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use of</font><font style="color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> intravenous iron.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;HIF-PH inhibitors represent a major advance in the treatment of anemia of CKD,&#8221; said Mark Eisner, M.D., M.P.H., Chief Medical Officer, FibroGen. &#8220;Roxadustat provides a novel breakthrough for patients who suffer from this condition.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This approval follows the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize roxadustat in June<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> based on results from a comprehensive pivotal Phase 3 program comprising of eight multicenter and randomized studies, which involved 9,600 patients worldwide.<sup style="font-size:85%;line-height:120%;vertical-align:top">7-12</sup> The results of this program showed roxadustat was efficacious in achieving and maintaining target Hb levels (10-12g/dL) in patients with symptomatic anemia of CKD regardless of dialysis status and irrespective of prior ESA treatment.<sup style="font-size:85%;line-height:120%;vertical-align:top">7-11</sup> The safety profile observed in the roxadustat development program is reflective of the CKD populations studied and comparable to ESAs.<sup style="font-size:85%;line-height:120%;vertical-align:top">7-12</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EC has the authority to approve medicines for European Union member states, as well as in the European Economic Area (EEA) countries Iceland, Norway, Liechtenstein.<sup style="font-size:85%;line-height:120%;vertical-align:top">13</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#4D4D4F;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The EC approval of roxadustat <font style="Background-color:#FFFFFF;">triggers a milestone payment of $120 million by Astellas to FibroGen, and FibroGen will also receive royalties based upon European net sales. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">About CKD and Anemia of CKD<br /><font style="font-weight:normal;">Chronic kidney disease (CKD) is a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure or end-stage renal disease, requiring dialysis or kidney transplant.<sup style="font-size:85%;line-height:120%;vertical-align:top">14</sup> Many patients with CKD die of cardiovascular complications before progressing to kidney failure and as such the prevalence of early kidney disease is much greater than end-stage disease.<sup style="font-size:85%;line-height:120%;vertical-align:top">14, 15</sup> CKD impacts one in 10 people globally&#160;and is predicted to become the fifth most common cause of premature death globally by 2040.<sup style="font-size:85%;line-height:120%;vertical-align:top">1, 16</sup>&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia, a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin, is a common early complication of CKD affecting approximately 20% of CKD patients.<sup style="font-size:85%;line-height:120%;vertical-align:top">2, 17</sup> Anemia of CKD is associated with an increased risk of hospitalization, cardiovascular complications and death, and can also cause significant fatigue, cognitive dysfunction and reduced quality of life.<sup style="font-size:85%;line-height:120%;vertical-align:top">4, 18</sup> Blood transfusions are used for treating severe anemia, however, they may reduce a patient&#8217;s opportunity for kidney transplant and can increase the risk of infection and/or complications such as heart failure and allergic reactions.<sup style="font-size:85%;line-height:120%;vertical-align:top">19, 20</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">About Roxadustat<br /><font style="font-weight:normal;">Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors, that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. Roxadustat is also in Phase 3 clinical development for anemia associated with myelodysplastic syndromes (MDS) and Phase 2 for chemotherapy-induced anemia (CIA).</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is approved in EU member states, including the EEA countries, as well as in Japan, China, Chile and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Several other licensing applications for roxadustat have been submitted by Astellas and AstraZeneca to regulatory authorities across the globe and are currently in review.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia of CKD in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia of CKD in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">Important Safety Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full European Summary of Product Characteristics (SPC/SmPC) for roxadustat will be available from the European Medicines Agency at <font style="text-decoration:underline;">www.ema.europa.eu</font><font style="text-decoration:none;"> <sup style="font-size:85%;line-height:120%;vertical-align:top">21</sup></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">About Astellas</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc., is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <font style="text-decoration:underline;">https://www.astellas.com/en</font><font style="text-decoration:none;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">About FibroGen</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit&#160;<font style="text-decoration:underline;">www.fibrogen.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#444142;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Astellas Cautionary Notes<br /><font style="font-weight:normal;">In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#444142;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">are not limited to: (</font><font style="font-weight:normal;">i</font><font style="font-weight:normal;">) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets and (vi) infringements of Astellas' intellectual property rights by third parties.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement or medical advice.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#444142;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Forward-Looking Statements<br /><font style="font-weight:normal;">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the Company's product candidates, the prevalence of CKD and anemia, the potential safety and efficacy profile of our product candidates, our clinical and regulatory events. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may", "will", "should", "on track", "could", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year that ended&#160;December 31, 2020&#160;and our Quarterly Report on Form 10-Q for the quarter ended&#160;June 30, 2021&#160;filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;color:#444142;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">Contacts for inquiries or additional information:</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Portfolio Communications<br />Anna Otten<br />TEL: +1-224-205-6651</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;color:#444142;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">anna.otten@astellas.com</font></p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.<br />Corporate Advocacy &amp; Relations<br />TEL: +81-3-3244-3201  </p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors:<br />Michael Tung, M.D.<br />Corporate Strategy / Investor Relations<br /><font style="text-decoration:underline;">mtung@fibrogen.com</font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media:<br />GCI Health<br /><font style="text-decoration:underline;">FibroGenMedia@gcihealth.com</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">References</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Nephrology ISo. Chronic kidney disease. Global kidney health atlas 2019 [Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://www.theisn.org/wp-content/uploads/2021/05/GKHAtlas_2019_WebFIle-1.pdf</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol. 2013;14:24.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2020;13(4):613-24.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care. 2007;1:14.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6. European Medicines Agency. Meeting highlights from the Commitee for Medicinal Products for Human Use (CHMP) June 2021&nbsp;&nbsp;[Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7. Clinicaltrials.Gov. Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees). NCT02278341.&nbsp;&nbsp;[Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://clinicaltrials.gov/ct2/show/NCT02278341</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8. Shutov E, Su&#322;owicz W, Esposito C, Tataradze A, Andric B, Reusch M, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021; 1-11. doi: 10.1093/ndt/gfab057.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9. Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep. 2021;6(3):624-35.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10. Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021. doi: 10.1093/ndt/gfab051.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11. Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021;32(3):737-55.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12. Barratt J, Andric B, Tataradze A, Sch&#246;mig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021</font><font style="font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. 1-13. doi: 10.1093/ndt/gfab191</font><font style="font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13. European Medicines Agency. Authorizations of Medicines&nbsp;&nbsp;[Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://www.ema.europa.eu/about-us/what-we-do/authorisation-medicines</font> </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14. Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc. 2014;125:229-43; discussion 43-6.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56-61.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017 2018 [Accessed August 2021]. Available from: <font style="text-decoration:underline;">http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17. National Kidney Foundation. Anemia and Chronic Kidney Disease&nbsp;&nbsp;[Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://www.kidney.org/atoz/content/what_anemia_ckd</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18. Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19. Disease NIoDaDaK. Anemia in Chronic Kidney Disease: National Institute of Diabetes and Digestive and Kidney Disease;&nbsp;&nbsp;[Accessed August 2021]. Available from: <font style="text-decoration:underline;">https://www.niddk.nih.gov/health-information/kidney-disease/anemia</font>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20. Sahu S, Hemlata, Verma A. Adverse events related to blood transfusion. Indian J Anaesth. 2014;58(5):543-51.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;color:#444142;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21. Data on file. Northbrook, III. Astellas Pharma Inc. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g0r02nlhhqpu000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0r02nlhhqpu000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #>!/X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWW_@=-_\56S119"^LUOYG]YB'PMIQ_Y:7_\ X'S?_%4?\(KI_:;41_W$)O\
MXJMNBBR']9K?S/[S$_X1BT'W+S4T]Q?2'^9-!\.'HNMZPOTN0?YJ:VZ*+(/K
M-7JS$_L&Z0?NO$&J!O\ IH8W'ZI1_96M9X\238][2+_"MNBBP?6)^7W+_(**
M**9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M()HF^[(A^C"@!]%)O7^\/SI<YZ4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBC]<G]: -&D+*HRQ ^IK._L:)O\ 775[,/1[A@/TQ2C0M,!R;.-V]9,N?S-
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M?]7JMXH_VBC?S6C['J2\)JN1_P!-+=2?TQ6C10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!S4/]L+)_P >UE>3^C"+8I_%L4 :5%9OFZO-]RUMK<>LLI<_D!_6C[!?2_\
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MK.V *QOL.OWG_'UJD-DAZQV,6YO^^WS^BBGQ>%M+$@EN8GOIA_RTO)#,?R/
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M>$+^K9-']B6C\W!GN3_TVE9A^73]*TJ* (8;2VMAB"WBB'^P@%3444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 5+109A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK+?\M[%/81,W_LPH^SZLWWM0@7_<M_\ %C0!HT5F_8=0/WM7DQ_LP(/Z4O\
M94IY;5+XGV=1_P"RT :-%9W]C1-_K+N^?ZW+#^6*/["L#_K(Y)?^NDSM_,T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BJUQ?V=JI:XNX(5'4R2!<?G6>_BS0T?8NH1S/V6!6ES]-H-*Z
M-(T:D_ABW\C9HK$_X2,R?\>NCZK/[_9_+'_CY6C[=XAFXAT6W@][F\'/X(IH
MN7]7GULO5I?J;=%8GV7Q)/\ ZS4K"U'_ $PMBY_-FQ^E'_"/SS?\?>N:G+GJ
ML<BPK^&P _K1</906\U^/^5OQ-EW2-=SNJKZL<"LRX\2:+:L5EU.VWCJB2!V
M_(9-1)X3T4/OELA</W:Y=I2?KN)K3M[*UM%"VUM#" , 1QA<?E1J'[A=W]R_
MS,O_ (2:&7_CST[4[OT:.U*J?HS[11_:&OW'%OHL, /(:[NAT^B \_C6W119
MA[2FOAA][?Z6,3['XCN/];JMI:CKBVM=Q^F7)_E1_P (VLO_ !^:KJES_LM<
MF-?R0+Q]:VZ*+!]8FOALO1)?CN95MX;T6T;=%IEMO!R'=-[#\6R:U%547:JA
M5'8#%+13,YU)SUD[A11100%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!B?VOJT/-SX>N"HZM;3QR9^@)!H_
MX2BTCXNK34;4]_-LWP/J5!'ZUMT4M3?VE-[P^YO];F1#XHT*?.W5;5<=I) G
M_H6*THKF"< Q3QR ]"C@YHFMH+@8FACDQTWH#_.LZ7PQH<S%FTJT#'JR1A6_
M,8-&H?N'W7W/_(UJ*Q/^$5T^,?Z-+?VOKY%Y(,_F31_8-VG^H\0:FBCH',<G
MZLN?UHU#DI/:?WK_ "N;=%8GV#Q!'RFN6\N.BRV0&?J5849\41\D:1,/[H\R
M,_G\U%P]BGM-/[_U2-NBL3[=X@C&9-$MI/:"]Y_\>44?VUJ,?-QX=O5'_3*6
M*0_D&HN'U>?=?>O\S;HK$'B0#F71]7B7U-KN_P#02:/^$JTT??6^C ZE[&8#
M\]M%T'U:KTC?\3;HK$_X2_0 <-J42GT8,/YBIX_$NAR_=U:S_P"!3*O\Z+H3
MP]9;P?W,U**H+KFDN<)JEDQ]KA#_ %JREW;R#*7$3#U5P:9#IS6Z)J*8)8ST
M=3^-.!!Z'-! M%%% !1110 4444 %%%% !1133(@ZNH_&@!U%1F>$#)E0?5A
M5>35M.B_UFH6J?[TRC^M!2A)[(N45G'7]& R=6L./^GA/\:KOXLT!.NJVWX-
MG^5*Z+5"J]HO[C9HK$_X2W1&_P!7>&4^D4+N?T%'_"4V+<);ZDY]!82\_FM%
MT5]6K?R/[C;HK$_X2)B?ET/6&![_ &=1_-A1_;&J.,P^'+LK_P!-)XD/Y;J+
MA]7J=;+YK_,VZ*Q/MWB&3F/1+:/_ *[7O/\ XZIHW>)Y!E8])@]F:23^06BX
M>P?5K[U^AMT5B?8_$<W+ZM90'TALRP_\>>C^Q]5DYF\1W0/_ $Q@B0?JIHN'
MLH=9K\?\C;HZ5B?\(V&YEU?5Y#W_ -+* _@N!0/"6C$YDMI)3W,MQ(^?J"V*
M-0Y**WD_DO\ @HTYK^SMEW3W<$2^KR!1^M4)?%.A0G#:K:MG_GF^_P#]!S4D
M/AW1;=MT.DV2-ZB!<_RJ_%!# ,0Q1QCT10/Y4:A^X7=_<O\ ,R/^$IL'_P"/
M>&_N<]##9R$'Z'&*/[=O9>+;P]J+-_TV,<0_,M6W11J'/26T/O?^5C$^U^(Y
MN8])LH ?^>]V21^"J1^M'V;Q+-Q)J.GVP]8;5G/_ (\V*VZ*+![:WPQ2^5_S
MN8G]B7\O-SXAOF]1 D<0/_CI(_.C_A%=.D_X^I+VZ]//O)&Q^M;=%%D'UFKT
M=O33\C,@\.Z-;,&ATNT5Q_'Y0+?F>:T4C2)=L:*BCLHP*=13,Y5)S^)W"BBB
M@@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J&2SMICF6VA<_[2 U-10--K8IG2--88;3K0Y]85_P *
MK/X9T*3[VD61_P"V"_X5JT461:K5%M)_>8W_  B?A_MH]F/I$!2?\(EH7;3T
M7_<=E_D:VJ*5D5]9K?SO[V8A\):*?^7>8?2ZE'_LU)_PB.C?\\+C_P #)O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g0r02nlhhqpu000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0r02nlhhqpu000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A 64# 2(  A$! Q$!_\0
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M/Z9I@>D4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0@,"" 0>"#7):[\.]
M%U@-)#%]AN3R)(1\I/NO3\L5UU%)I/<VHXBK0ES4I69\]^(?!NK>''+7,/F6
MV<+<1<H?KZ'ZUS]?44D:2QM'(BNC##*PR"/<5YEXN^&2L'OM!7:PR7M,]?\
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MFLKP0SRZS,SL6Q >I]UH [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[');>:BGY5;(9?:M^!]5\0J$N(/L5@?OCG?(/3Z?YYH Y*SD6;Q7%*OW7O
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M^NRT44 6J*** "BBB@ HHHH **** &G[XIU%% !1110 AZ&D3I110 ZBBB@
MJ&W^ZWUHHH FHHHH #TIJ=*** '4444 %%%% !1110 4'I110 B_=I:** "B
0BB@!C=13Z** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g0r02nlhhqpu000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0r02nlhhqpu000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I :L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHI"0H))  Y)- "T54T^XFNH7GD4+&SGR1M*MLZ?-GN3DY
M'&,5;H$G=704444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJI/?-;S[&M+AH^/WL:AEYSG@'/&/3N*!-I;ENJ-[>3V,
MHE>'S++;^\= 2\1_O$=U^G(]QT;9:[I>HMLM;V%Y.\1.UQ]5."/RJ[*_EPN_
M]U2:=FGJ)3C)7B[BQR)+&LD;JZ,,JRG((]0:PO$UVC_9-&\X1-J$GEROG&V+
M(W<]BV0@]VJ6.WGTVW2\M0&C9 ]S:D@ G&6=#T5NY'0^QYJCI=K;^);'4=1N
M#N74/W40!^:&)?N?[K9^?V)'I5)6U,JCYTH+K^77_(Z9$2*-8XU"H@"JH&
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3!+&TK1!U,B
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M5K#4+35+&*]L9UGMI1E)%Z,.E96I^-/#>CS&&]U>VCF'!C4EV'U"YQ^-%F]
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MO_?6,4)-["NCJ:*KV5]::C;+<V5S%<0MTDB<,/S%6*0PHHHH **** "BBB@
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MRC/YGG\:]E^'LSS^ -&=SEA!M_!20/T%%5)I2"&C:.FHHHK T"BBB@ HHHH
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J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>fgen-20210819.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-19T06:04:02.6630983+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 0f7a9da9dd1942fe9de0abfc928a7dba -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:fgen="http://www.fibrogen.com/20210819" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20210819" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20210819/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210819_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20210819_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>fgen-20210819_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-19T06:04:02.6630983+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 0f7a9da9dd1942fe9de0abfc928a7dba -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>fgen-20210819_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-19T06:04:02.6630983+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 0f7a9da9dd1942fe9de0abfc928a7dba -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20210819/role/TemplateLink" xlink:href="fgen-20210819.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20210819.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>fgen-8k_20210819_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20210819.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20210819_20210819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000921299_20210819_20210819" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20210819_20210819" id="F_000004">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000921299_20210819_20210819" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20210819_20210819" id="F_000002">2021-08-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000921299_20210819_20210819" id="F_000003">FibroGen, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20210819_20210819" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000921299_20210819_20210819" id="F_000006">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20210819_20210819" id="F_000008">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20210819_20210819" id="F_000009">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20210819_20210819" id="F_000010">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20210819_20210819" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20210819_20210819" id="F_000012">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20210819_20210819" id="F_000013">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20210819_20210819" id="F_000014">978-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000921299_20210819_20210819" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000921299_20210819_20210819" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000921299_20210819_20210819" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000921299_20210819_20210819" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000921299_20210819_20210819" id="F_000019">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20210819_20210819" id="F_000020">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20210819_20210819" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20210819_20210819" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140199219742936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 19,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FibroGen, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M _(G?N=LIR^.B1W*6LHW>S(/1PW7$K&8!<9*4/AX9U,6QU8)./X^B3:*=]K
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "OG1-3)!Z;HJT
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M2P$"% ,4    " "OG1-3!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *^=$U/@2VPA[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M *^=$U.97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ KYT34]0NO) X!   31   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M *^=$U.?H!OPL0(  .(,   -              "  7P,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ KYT34Y>*NQS     $P(   L              ( !
M6 \  %]R96QS+RYR96QS4$L! A0#%     @ KYT34QPX9>H_ 0  / (   \
M             ( !01   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *^=
M$U,D'INBK0   /@!   :              "  :T1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *^=$U-ED'F2&0$  ,\#   3
M          "  9(2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  -P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-8k_20210819.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-8k_20210819.htm">fgen-8k_20210819.htm</File>
    <File>fgen-20210819.xsd</File>
    <File>fgen-20210819_lab.xml</File>
    <File>fgen-20210819_pre.xml</File>
    <File>fgen-ex991_35.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-8k_20210819.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "fgen-8k_20210819.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20210819_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20210819_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20210819.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20210819",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20210819.htm",
      "contextRef": "C_0000921299_20210819_20210819",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20210819.htm",
      "contextRef": "C_0000921299_20210819_20210819",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.fibrogen.com/20210819/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001564590-21-045220-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-045220-xbrl.zip
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M88J!4$JAGP3(E*ZA@/;?"6.CPSY0S&A ?&P?-F-=T>SH2W=4*T.<T?4L>%5
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M1X+60\AB4*H##7W#4G9TXHW/]?$I>^GOUMIJI5F3RZ7RRKC^#U!+ P04
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M!L!?\;# QE<7_-;TFJWFZ;NSC8;WT/\.QPCT+S<:>J/WL!/([Z#5>=<>H4Z
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MT'\^8_/$C3Q2_V8G.87C?SWS\7]02P,$%     @ KYT34ZXB52WU!   4BL
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M;EO6#GO+D>*.5&.WYGEU-Y6V-N++ _E%/9'V&XV&FSS=BFJ6)PAF???S8W=
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ML^7CHJ(I)O\@5D;+?S!R;MP#5F"5]F*.:JZ?F'_F^.+'?P%02P,$%     @
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M@[7=',>-LEFI;Q&MO:[NBN&%KNE  +IX0%W"[ID]QO1Y> WRG<DO:""[8_1
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M*K%PF<F=PY2Y/;-&6F==8I4,'2KF.51>GE$0V/D:XD,P2B9@B6K9!GA[US]
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M37)8Z@IV$^=4.O1/\M7U^W@9(W-ART%^4'&3G^SV6GO*EPLVO[]M;,=ST 4
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M^6+#:;;$>2*CU,]\'<F@T3AXOR)61ED6=QJ-R63B3-8=G0P;YV>-418&&XU
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MDIZ7T"BTSA"$\F$I%1$APDC8$(R>C3"RJR./@UB.P%8%6E^0D$TP"1HEE!<
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M(J?I[D+Z[>E3Y4ON^&!TTUR@XL',:DXELDV$44LDG$F=I\)/=+0LSO)@IN_
MA86.7=3EM:71H0<SZYF7^J"GR39J#.1I3"F5:I2A 7;.&7:E,0 @.]F%LZ,_
M36&C"DMHC6D?'KOG" 9MY8_\:*R#L1T_44.V<08(<R@ 6*P&<Z;A$47L5 '(
M 16F_ N8X0=-/MAB/;$ DF(>#WJR#$D,R+6AFV(W'_2T\Y0"1 ]ZBI<4JO,C
M8GL_$=M%K9_.G$#P;R@_<N9L+".WA/3SX?AJN&?>YSV1R84X\-.Y:.JI<XB_
M>R-?#8SS"OWW@=Q'NJC(@)3N:<5;*,.G$FN 4A0,X@H7@5(%,[=TI$6:D\<
M;U^'BZ'/'Q[B'5EG/F@PT*2C%P*]15PB%=TA!5M*F[=Z<-)=,TFI+%,F,VLO
MQEBGB8;"Q!;2QX=Y2'XC9VD.3T[71*RI G-,H04_*B)^>3;2"04'DJIG*=[F
MD;IC>&_+!O?ZG,; [2 6,*BI82K);F>B1BI*:4ZQ/]89+6%$>:5U$YF4H;G*
M3\GKA)#P+8U=-DZD"4OB'TT1#@_3S3WXJS7KE%KC[HF=VE:S66%QG00>?!9U
MUQCF=KU51&[/&3^8)18)@V(5Z4A/,(L*C2<R-7$?Z?JLE2- '8CUF/WK2FB'
MWMOHSF&_ #2KK29N/&QXQVL<6_I<7L=&]:Y-F)B 7D+ B()W8TY[@/9@)?CY
M,[5U#R1K54B6RH'*ID2I@4]AKWZJ$MHQJRTK)/-F::.2L(SD!L%LPO0;6FJL
M8XOD4LL4'B_0!#N*G P%,.Z/!7ZHQ-NK1"B_/<YQT@9:K02V(!5E\ITB+'4B
M:;?YP!B^#/LJ84XFZ<<X$Q4$]'<QD'8 2P9EX8HN&!KZ] #Z=)9U.W)5 #:I
MB?<4N9W6Q+&OW%$&)94I/[ISGF?]!Z/<"Z.4UA,27]$0-RO$6'F)O1X.54)@
M"+-6:48IOEA."U3V/]A!^B8@UNI/RQPUL>.L0J5:KP+-2^P6I.2"<FD?YC65
ML%,@A[& .?S-&1M&T.>IQ+T?;_5$=6\K99,WXHMEX=I;LD2WK_.,=3YMR%S^
M]$4_$8T;E 'M75/=8C)G9:(4&UM\[8Y@2%R $$8>8!-8)"\'4P;:&%@[W""/
M3*"=XP6AG HJE,AR#I0'2G+@O;A6^@%7'"1"@7'!U4-ETZ[VME3V\$?N)X0+
M2@N.R^T 3+,8.NS.=KJU8:WTB8RF"Q"#J V32HM<R!57DXE4L(+M4S/J$9:Y
MM%;:-LA6F@.PD:H&*H1H*W*9"/)QCG*QE# %"'1G64G.#<X(9B^[.P5JHE7D
MJ&]4-& J86PB'NN Q;))^KZBG+G-!PU PE"G&5$KI R,-$$$^DEH2DX\+&Q4
MCDO<U6YN-.^AT*!E<;F9ZCWJGIL)_CT;I$OIGF]MD(R^J5'"%XJ D'QHW?+2
M8R96,>Y(*40C.28.(B_;9GXI]LWQ2=,9Q4)!L3L+^,$;LRQ?S>@DRSQ7)_%G
M:7BVEY]\\)8*B)/^6EQ2S.BNC-4&8VU?5<*R6)$BHS)Y"9_(3R]X>3J-N;CZ
M3UY#[7K%0N1A$3%FV,60;'R-)%7K' ;XQ3#G&"X^9#?!FZ:E3C9E+4LK9.Y*
M$](>SRU-7O'6&I;*4[,$2'E.%. Z35)DM%,I]CLIDOTU07[CF&([4!Q3MAUF
MLF22S-:5H0$=QSK)\HA6,%AF$$I*%<0W#I:EOQ\QLQB2-/0BP5D[2\HURR2;
M5]U!H""J+F9F$LIW9B93V?QMH'(5O_PGX*192/"FX&CV"Y(U4VA:^&*U^1H'
M"F( V4Z$*;6D%$KAM-4N)<C2F@%$T$RASA;K#6J$:>:5(EU)X2W6#D7D<J9(
M8/[UT(2X9Q<R@I@-#!';)2MN"F@I$BYD/]5)7.H"4W]D=-"N43-Z$LWGA48J
M=JF49[X<(S4:"#0H8E@NN)U-035RP;T4RZMMPRFN@G*"M*84O$FGD9=0I9U8
M/=GOF1(\,W:;AW'))(#ZB8RGILV#@QP\]NK>47?M/L/\=S+O3ZGXH_W]BC]^
ME&(\^CL^&."ZH+J*I@)JTOIE,9P&)1OD7+O(H;2#[BQBMAAK>RMC&7&&*I+\
M)S HH0?C,Q+O- 7=EC>F+);"+]3+0_66[N[J_K[1AE0)/??%^WWJ1^D19J+H
M$"E'8#F7D@P&!L\0#<VB$CMB2,X-%FG>Y^R*-Q?ZX>!""MK^6T7*E:;8@*V"
M3J9EQ'*A<I_PND5)0$MNGE 1'A"X3]F0L:\FSG=7S8^6@>=VIHS#,9WI5(@^
M@ HC:E/J.F>#;2(@5 G,;V'M%V*)!9/&P"91ALL^PZ[0P G!&N* F;Q8<3!A
MOYHXSY,+-:V)LSQ-"0#8^N0]]N0F2@:0$0QY!&K'BDDN>E8&N8[9]SS(TP'@
M0:TB5=U! JYV*D18X-7O1Q2JJ>8&(*L0C$2"PRY45L;FN[@G%L"*1G1SFGC@
MRP:QSK]!$X['EZL%V,NP.&JZ>&RB\T <@:.0'$5R"'LF]W84T6]XOY^*<J \
MP2"'52H#[KT\Q-S9N;=I<O!D$< EN WKT3O=:_3"T[VU1>/ T7W2Y+.6:%,9
M<4W.7BPF)'CZGG)9!G74R4&VA!QBS)=.05*A=!2-1G^6U1,M#L $6'DI[AJ[
M:16N]L-P%AZI6!G_NK!*5SM =+S-+4\@N.V2OH;5K32 VWADS)^X*L]L_#.,
M*7- <=#<A"'[>4H"PHH_I,0 Q^VWF]6V1\[8L61QD09W6DJ30X"S6V#0U]J%
MG\\I7#XM0W+NP&!93U'\S_8S$ ']P;02'?-M!IF&P=PP9$XQ Y<C<,;B40C#
M2_)A6FT.M4D%FP$9@:(BCT*5E0'?2"DO)<PXH,E9*_O*IV8DTRUUHCT.,,)2
MYPD90J)!#>C9M!52](!Z2IE2:@JR"9TG& T$D>;H-''VR8Q.$^,9*WST]SLJ
M@)^>M;8W=FVD<L0HA/NQ4AWD!BLS:;&A?>J5HDFI3S$-E!IP>Q'I2:"\H;+-
MXGE&&U7G3S+ECB)# S^J=*(,?!5X'","\ZF$%A?+)(M4DE*)KHGN@$BXA1I@
MOZCAMV0^*.7(2PL40SDFZ&.#02KSIU:7(==Y9'E"8<](CR5'@%,*NG-)'KX<
MRR!7<R5PV""\8P[U9[:Q9GNRQ=A/_8S),%%]O%1?I.KIW+O4'GPGB^9GT+:A
MEM:Y7Z'TOU4%YW]:?+3 T-_."GY=?;UPH 8KZKZOK]35H75](1=0>*Z&ON N
M3>LI%-5I54>!/Q.Q'ZN U</@4LL]ARCY7BS;[/#P_=@A)X<)SD ,[E9\MXIV
M@<KXS#DV9C919$O \*L4TCQ,] 2:J+AR[_P-+NU;76PZG6U-;JD3YNN++L4G
MC*YG'3^_!BJ.+1W[SY I61)+3[%1 91-H-R<&_^*9D#<%"M<=E /-T50D^QU
MT>3KC^Q8'KG^&A'KFT6JQ:D,$S4.\E#VF39@8[].^R9&7,@*!UF[ 1M!^HHZ
M01AW7#?K2YL8:-=V8?+V>]A5*M:V'8_83H,"7$J3N7!45X^[\ 9J8C_'"L!C
M(LQM.A*+S@#51U.QNG^ROV:[[SU(ELQ&&"#. \R8'(X!22 'IXY.7Z_=Q+38
MU/R7^ Y\$[@=9$BL9;@7__A.!4575F#=V_E+M_,S[XQ]]R3C(MK=]SI3Z4U3
M:4=1419,@#)1@2GHX3!KR%'.4'JJ.+:!ZW 9Z!GU(BB+"Q2DJ!77!(4H5)*I
M(0-G\%\?&E@-4L.,)M12&9M!'.$BBIIB&A2L(JD9<$T+?6';U>L%"JW\6+)U
M9+25<X$*-#2SKRW3F1WC<LZ8K?I37%T6@<]ZD?Y6ZDU2*WD8SS+[=ATDVP%7
M?-O"WHK$5'3NW"DKO@EDV<)O1J8F'I9'YC7ENU/["42<2JS))7!$5T0Y1[W)
M@+'=H*Z'//!L40$^RDVW&9=XLX'D)@G:"SJ\$E.Q40&=<@T2<'HZJV2^FKB.
MZ%%VO;BIB1Z"+_IY=D5QX%/*IZW_R*<]V.S6[37X U'9G]?)A4(,_- WP+<C
M5F]\@)Q_XRO7K#O*6@V6FA-4JBA&+XO%;!L&%)^<I+8ZJ:@]X".O[!$,4#\+
M&-X&U6MBU??7K'ITI\#2U@TF2R$&04YJS(Z&*W&IAS&G/"V*>]C:"=P?^G&D
M^*KQFE6_TAS.4E7XYH02NC5N18%4"WTK8W&GB\'G=*[2ZN>&LU$9UN>57Y+J
M53*A.B2N_F*L-[N'=%T5VZP=-"_X4K$RY5"-K9!3F:D *Q(0--#JV*<FF@%Y
M'M9B5>;S-XH1X)4RVC^F8&^"*?.1UASM@45//(Y=D!E9KJ_O%PG=*;IZ;U-Y
M,+'^2OK"PI0%R2A99'66F"L_FTO*5AR(M3*>:.VQ->2+\(VN(/U!;!)YQG,&
M T,0LIPB0Y$Y58N\6>.%)&7 $%_XKEK$Z4^15QZ(-2@3I*\M%CNV6*Q78K&;
M0GE[B(!A 5)8P)'I=0#:]-YQ5#A/"N!.'KR%TX3MBS/9&/G/U5TL'>C&&=QL
M%J[X6UD=1SZNYWNS[/)\W7W14%%4HLZG?6W7'A\B9KH8*RU\ U[BLMO0YZ6W
M7C%N5$+!31&E_W -)>?P\67S7;OLMO!TC/.D^Q^-/6%C:ENU*T7%M)6TQN+]
MU?X292G*\X[H,IMK\(T)LA7] )+AK'H6$&ZZ4A,KE$^DO^F(' QZ1:'L!.)&
MK]WB0XJ#N1F]HMG37PI]N'Z,]=$[]I/&_+)P"OEBTWC +XL=,^,:N[I2G#/F
M4R1CHA./7,8 ?@O%W%/J4[C.$\12,3'2@5AI&= /IH[X #HON$E4LGRMGP0E
M024YI9]T_=Y[!A5<X<09>%3J8%[L[)!#LV58M>DE)J8@%6$+1JF=]%*IDXH2
M'02E<,UU,.MHJ NP,Q,,*\XEDV>TXCF/'&3(")F4[KBG4C?Q^X8"-*MN%!$)
MSQ2EK,AIAKH*1:M9?U=&M0;P+G')%'C(#,2VQP2.]I5KRK?66WQ"='/6E4*C
M_S.7]!@<[,+E&_RSO,$?YJKJN-03+M:;YM1I\Q')NPT%TH]Z"M;4%D'A;@<%
M]*P>HMP[H(#:/)FY!KUP?U/%P3LS9$)=E^(H&E.37F*8SS71%V7*OP@(![#U
MX 1B#G" ;V(2G^>FHDL<ZE9>X <DQVFA+TECE7W<9:B&EC7A>Q'779!N@$J!
M(RZ+T_KRF'])D>$K[[P<2=0(JP/"TB1,CY?1)/ $O@FL_ ;-@W,AB]O#E1O!
MB5MBA&?/GGV_W/W77-C76-7-6.;2JF[,0Y5)?H1+YP^FCW=6WY\#Z+!\61P/
MXD?<1:JX>90>O&4K#"HQULZ74*+*1 \]*3HK8H&=&>C UVRB\J@H#C9> .RP
M%!]@K2/S_OS@N"/^WJJWVQOU=G.SOK6U^?G'JGT9B1Z,4WWC[),$D1Q-1/I'
MM9KAIN4)M^"@>[93CYZ'9X58ADWW=!)KCO9UO;%FU^PG&<:[P'M!E;T-.S]O
MU=?KZ^V-#?S3;(G/G\5]SSMV+P4FCW0/YXLSGNHJ2_3>,7QW LPM52#.<RHL
MH9/-%OFV9Z,CHE%"_T7FO;%^"C/<YA]+\N.+G/Z4<FH;/W)J#S:G]L5R_6 $
M^8<Q_UJ4I=X!:=7CF[TC<<A%K%^HZ0IKPH/]8^CZIA3V:C3VU5W 6]CVZ^?T
M_+$4DYXICHJZ:K$18'X]6X^GD+3ES)ZM,15'/>V(Y<<F.>(-GUI3?&RX4,B,
MP"H@YH[XWZ[KFNBQ?90=!13_SQ'=N>Z:SNU*JNFQ%FGDT//$)W'=AO,;>1QH
MZ:4-NE.CN=EX\^ZP2Q/ZG2;T^Z^J__HH4/66$WN#&Y7//:*-:SMB/_2INV(,
M;Y8J><5Q3AT2U!0%_"5=3^=#JD$]VJN)-W@AAQ2G/JR)<QVF.A+X^% FB9^*
M=S6A,B$#.O/<5(+:#).,I'G,##WHQ.=&*R[!GS\V:GE):D>8AMG4G#]"V:4L
M][@JH#B1Q1[94,1.KRIM_><1G]C%,7<*X$I'O#K9*_C6(>Y;WVUM=-H;3V9W
MUQWQJXZ&XN3D-VHOI;TZ]@5>GT(ZJ&[V[)A>N]K/TOIK/QAI<89+=$Q]:MW9
M=MKZWLB>BN$I<S 1M;&%-/X5)._1>5NI6*]OOI\=)E14O"U_0JSX8)\?9<ZS
MH X\WU7TR%EJ TDQ)#:_4S[W*L1O\D1Y-4[60#M,BV=?00%!_HO1WSJ<Z]AM
MK:]NK'6V6NOU)[3+&X[HN:,0J%F<O:V)?6A4DLMC1YP7!P?->F^O?ORJR?)6
MQ#-5W*G363QL25>W:%:R26<;4G[9]B.ECOB09HI+GJG]$9OIAV(/ ]->-+=W
M6YW6T]F#38>XW9R+?7)0$Z\A7.<./=FPDC6WNW"UCBJ:HLWSI$QS-P8YUCWQ
M(6*ZM39V=U9;:QWU?&-G8_W)D&_+N;I5UL$GBKF8:[5,:57986M.N_["PZXY
M6<F)2D:9YM^O"CSFVG<;*FI$:I(V0K.P^FQA]:+)1M7#8C'UHARISLT.]3Q5
M=<A[7&^WH,;J'[&8.C_K]XEADVVCPRE3;A+ESAL]7GC*%?/ >;6+HUL*V4'D
M&1-DG^=6F)C5@]X9@$#Y&',HRY[I\=@OCPHYG0*@*Y6N =CNG3?;[>WGZQLM
MYYOPBSN_Z*$>-]RLW:!CPAN5R3RU[7X.%3K*,ST6T)^]_*=GZ^WVKI[X[I_B
MUYHX2/F$>DT8YAS@+9'>GTH HW0C+X$F?57#+N>I"UM3XI:SRV=3+#N1XFI]
M7&*6A:-D.J:AF<[QJE4.F =\UCDVOM['#GHU4WK0U^QG4*F(/8)^*E:[QZ>]
MM=)G8KX#%Y>'LS(K[8I6O07'RM-^1[2:3JNYL]Z(O*PQ',A^<W/[R6S\#N1<
M3Z&1]['/9WH($]K;!PN,L#$].!7O@!MZ;VK #IBZ9&!ZHFE;!U*<=*_:;8#]
M>E'Q,],)[W54+P\$*C2 4\#$(_#%F8HM_;=6UX$5H6'7-Y\,K<%'9!O'*OI3
M1HSV9S)WD #'D1\(I^"=3D 0>@,O\%1K:#-\VI,C*=Y<1?&9.,T[=E><54QE
M/N:IS]PM8_;D,S)QI32TGLX.M>BLGG34!SF)^ =!O3<"W2=39O9+WMJ_Z,&G
MIW#"(1($/L\!/N&-0UL=7[51I5LPDXM3N7B"\WNC\O9+E7<V_X2.L]ES-8HC
M#=DY<\1;T87 :K?J6D.<UMLD3]OKV_7-2_+TE-(KFS_2*X\DO?*(M,+EFO.'
M,*M6VRD>NBS>5J'8'$+KN:.?GK4WMG9#?TCH;(;3_B6#($]\\<L70#9YCY@M
M)<P&KS.J ["KH&9ZY]42P+;_X?C#R='YP6=1VY4M7P]AOQR"E.M7&-'6S@.?
M_$VJAAZ12--&7!/TZ-J';]GV SV87?.=HA;<+E'/T\9D)(D2=4\W[-&6*8]3
M+T_)N***XO'NU88C/GS4H@O"FA.?BNIT\Q &T<\33/J: &MQ)/5<@PO?/"B.
M;RHZ&!VC5 A%<0P;_X0R@\+AM(J- K;:FYUV>Z>^L;Y;=)-3MF5CO;[U=* P
M157S?M^7(]%]1\=$CF0_D>*W=Y29&LF/E*1R**9<#4]7@JDW2S#1J>1#ZN$D
M=9_WJ68>+N AGV7/9TD2Q;=VGZ^VUSJ;6_6M)^1K;%'[1-&-R*%2DX\]45E"
MAQYRHP8=@65R>:M'AR<'=$H)]>5$PTH8UF9U7Y5BL%_F@,A^@H#;],_SKY/>
MM>K*)),YM4<97CI\*VUX:B#AMS2H&R6U_\8Z\-WI[PFWN#0HR]MX\VJ?TKW;
MO[_2^B)0V5-,]K:V 5X*;6-#'J_+ ^3F\GS+LW/?S/ 8$>5=A.;[LU%DZLGR
M_&[B#+^[%]Z3VZ#G@ 2)?Y&2^[Y?$V]TX*4AZ2Z\.5?P^^F+7DV\E>X%O7Q+
MB4^*:E&+F7@-74C)\GHE69XG8\7=R]4'NA2G4!OX4?28%29-5K+W?95-Z-CK
MA:>?V.9/QN*7T^A;NZUM2E+M/)T896O'*57:^R.]+_?E.Z<2/UDN+YV9N,W4
M+"M'N!N9S:#N^T/JSQP;HLX/L/O-)"[R/>\"_XXXWV T:;W2[M$P(EFW5K-A
MA/"I"6"[Z5"0,R<9.U0AH)F$EZJHA)ZAWU@E=.3DV/9:E_VD_<4G^)!=A><9
M43 ,8I)F(XO;-I^O;@)& *<]H9@E!6;W02ORM\G".O2$S&S43V!+:^+HZ,@1
MRSH2[L4]^'HEAH\^$KGU_2*1+QIT!A\%)!NC+ SPXO\!4$L! A0#%     @
MKYT34W#7\":U!   8A8  !$              ( !     &9G96XM,C R,3 X
M,3DN>'-D4$L! A0#%     @ KYT34S%D^-(>!P  #DD  !4
M ( !Y 0  &9G96XM,C R,3 X,3E?;&%B+GAM;%!+ 0(4 Q0    ( *^=$U.N
M(E4M]00  %(K   5              "  34,  !F9V5N+3(P,C$P.#$Y7W!R
M92YX;6Q02P$"% ,4    " "OG1-3GVT09%D1  "+DP  %
M@ %=$0  9F=E;BTX:U\R,#(Q,#@Q.2YH=&U02P$"% ,4    " "OG1-37!"J
MI3 @   2I   $0              @ 'H(@  9F=E;BUE>#DY,5\S-2YH=&U0
52P4&      4 !0!& 0  1T,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
